Search Results - "Schuuring, E"

SP-0608: DNA methylation biomarkers of radiation response by Schuuring, E

Get full text

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer by van der Wekken, A J, Pelgrim, R, 't Hart, N, Werner, N, Mastik, M F, Hendriks, L, van der Heijden, E H F M, Looijen-Salamon, M, de Langen, A J, Staal-van den Brekel, J, Riemersma, S, van den Borne, B E, Speel, E J M, Dingemans, A-M C, Hiltermann, T J N, van den Berg, A, Timens, W, Schuuring, E, Groen, H J M

“…ALK rearrangement detection using FISH is the standard test to identify patients with non-small cell lung carcinoma (NSCLC) eligible for treatment with ALK…”
Get full text

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer by van Veggel, B., Madeira R Santos, J.F. Vilacha, Hashemi, S.M.S., Paats, M.S., Monkhorst, K., Heideman, D.A.M., Groves, M., Radonic, T., Smit, E.F., Schuuring, E., van der Wekken, A.J., de Langen, A.J.

“…•Limited antitumor activity of osimertinib in EGFR exon 20 mutated lung cancer.•Objective response rate was 5 %.•Median progression free survival was 3.6…”
Get full text

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer by Donker, H. C., van Es, B., Tamminga, M., Lunter, G. A., van Kempen, L. C. L. T., Schuuring, E., Hiltermann, T. J. N., Groen, H. J. M.

“…In advanced non-small cell lung cancer (NSCLC), response to immunotherapy is difficult to predict from pre-treatment information. Given the toxicity of…”
Get full text

Optimising primary molecular profiling in non-small cell lung cancer by Schouten, R D, Schouten, I, Schuurbiers, M M F, van der Noort, V, Damhuis, R A M, van der Heijden, E H F M, Burgers, J A, Barlo, N P, van Lindert, A S R, Maas, K W, van den Brand, J J G, Smit, A A J, van Haarst, J M W, van der Maat, B, Schuuring, E, Blaauwgeers, H, Willems, S M, Monkhorst, K, van den Broek, D, van den Heuvel, M M

“…Molecular profiling of NSCLC is essential for optimising treatment decisions, but often incomplete. We assessed the efficacy of protocolised molecular…”
Get full text

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations by Langerak, A W, Groenen, P J T A, Brüggemann, M, Beldjord, K, Bellan, C, Bonello, L, Boone, E, Carter, G I, Catherwood, M, Davi, F, Delfau-Larue, M-H, Diss, T, Evans, P A S, Gameiro, P, Garcia Sanz, R, Gonzalez, D, Grand, D, Håkansson, Å, Hummel, M, Liu, H, Lombardia, L, Macintyre, E A, Milner, B J, Montes-Moreno, S, Schuuring, E, Spaargaren, M, Hodges, E, van Dongen, J J M

“…PCR-based immunoglobulin (Ig)/T-cell receptor (TCR) clonality testing in suspected lymphoproliferations has largely been standardized and has consequently…”
Get full text

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer by Heitzer, E., van den Broek, D., Denis, M.G., Hofman, P., Hubank, M., Mouliere, F., Paz-Ares, L., Schuuring, E., Sültmann, H., Vainer, G., Verstraaten, E., de Visser, L., Cortinovis, D.

“…Liquid biopsy (LB) is a rapidly evolving diagnostic tool for precision oncology that has recently found its way into routine practice as an adjunct to tissue…”
Get full text

The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling by Zwierenga, F., Zhang, L., Melcr, J., Schuuring, E., van Veggel, B.A.M.H., de Langen, A.J., Groen, H.J.M., Groves, M.R., van der Wekken, A.J.

“…•Understanding molecular pathways and the structural impact of NSCLC EGFRex20+ mutations is crucial for improving targeted therapies.•Molecular computational…”
Get full text

Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands by de Jager, V.D., Cajiao Garcia, B.N., Kuijpers, C.C.H.J., de Bock, G.H., Maas, W.J., Timens, W., van Kempen, L.C., van der Wekken, A.J., Schuuring, E., Willems, S.M.

“…Predictive biomarker testing has a key role in the treatment decision-making for patients with non-small cell lung cancer (NSCLC) and is mandated by…”
Get full text

Reliability of panel-based mutational signatures for immune-checkpoint-inhibition efficacy prediction in non-small cell lung cancer by Donker, H.C., Cuppens, K., Froyen, G., Groen, H.J.M., Hiltermann, T.J.N., Maes, B., Schuuring, E., Volders, P.-J., Lunter, G.A., van Es, B.

“…•A previously built efficacy predictor did poorly when tested on panel sequencing mutations.•Corresponding mutational signature attributions (MSA) had a large…”
Get full text

Identification of a methylation panel as an alternative triage to detect CIN3+ in hrHPV-positive self-samples from the population-based cervical cancer screening programme by de Waard, J, Bhattacharya, A, de Boer, M T, van Hemel, B M, Esajas, M D, Vermeulen, K M, de Bock, G H, Schuuring, E, Wisman, G B A

“…The Dutch population-based cervical cancer screening programme (PBS) consists of primary high-risk human papilloma virus (hrHPV) testing with cytology as…”
Get full text

Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL by Dufraing, K., Fenizia, F., Torlakovic, E., Wolstenholme, N., Deans, Z. C., Rouleau, E., Vyberg, M., Parry, S., Schuuring, E., Dequeker, Elisabeth M. C.

“…In personalized medicine, predictive biomarker testing is the basis for an appropriate choice of therapy for patients with cancer. An important tool for…”
Get full text

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression by van der Wekken, A J, Kuiper, J L, Saber, A, Terpstra, M M, Wei, J, Hiltermann, T J N, Thunnissen, E, Heideman, D A M, Timens, W, Schuuring, E, Kok, K, Smit, E F, van den Berg, A, Groen, H J M

“…To determine survival in afatinib-treated patients after treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance…”
Get full text

Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways by Booman, M, Szuhai, K, Rosenwald, A, Hartmann, E, Kluin-Nelemans, HC, de Jong, D, Schuuring, E, Kluin, PM

“…Primary diffuse large B-cell lymphomas of different immune-privileged sites (IP-DLBCLs) share many clinical and biological features, such as a relatively poor…”
Get full text

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 by VAN DONGEN, J. J. M, LANGERAK, A. W, VAN KRIEKEN, Jhjm, DROESE, J, GONZALEZ, D, BASTARD, C, WHITE, H. E, SPAARGAREN, M, GONZALEZ, M, PARREIRA, A, SMITH, J. L, MORGAN, G. J, BRÜGGEMANN, M, KNEBA, M, MACINTYRE, E. A, EVANS, Pas, HUMMEL, M, LAVENDER, F. L, DELABESSE, E, DAVI, F, SCHUURING, E, GARCIA-SANZ, R

“…In a European BIOMED-2 collaborative study, multiplex PCR assays have successfully been developed and standardized for the detection of clonally rearranged…”
Get full text

Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3 by Boers, A, Wang, R, van Leeuwen, R W, Klip, H G, de Bock, G H, Hollema, H, van Criekinge, W, de Meyer, T, Denil, S, van der Zee, A G J, Schuuring, E, Wisman, G B A

“…Assessment of DNA promoter methylation markers in cervical scrapings for the detection of cervical intraepithelial neoplasia (CIN) and cervical cancer is…”
Get full text

A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients by Eijsink, J.J.H., Lendvai, Á., Deregowski, V., Klip, H.G., Verpooten, G., Dehaspe, L., de Bock, G.H., Hollema, H., van Criekinge, W., Schuuring, E., van der Zee, A.G.J., Wisman, G.B.A.

“…Cervical neoplasia‐specific biomarkers, e.g. DNA methylation markers, with high sensitivity and specificity are urgently needed to improve current…”
Get full text

DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women by Boers, A, Bosgraaf, R P, van Leeuwen, R W, Schuuring, E, Heideman, D A M, Massuger, L F A G, Verhoef, V M J, Bulten, J, Melchers, W J G, van der Zee, A G J, Bekkers, R L M, Wisman, G B A

“…Background: Primary high-risk human papillomavirus (hrHPV) testing in cervical cancer screening shows relatively low specificity, which makes triage testing…”
Get full text

Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors by Ramdani, H.O., Falk, M., Heukamp, L.C., Schatz, S., Tiemann, M., Wesseler, C., Diehl, L., Schuuring, E., Groen, H.J.M., Griesinger, F.

“…Immune related endonucleases have recently been described as potential therapeutic targets and predictors of response to treatment with immune checkpoint…”
Get full text

Tumour infiltration depth ⩾4 mm is an indication for an elective neck dissection in pT1cN0 oral squamous cell carcinoma by Melchers, L.J, Schuuring, E, van Dijk, B.A.C, de Bock, G.H, Witjes, M.J.H, van der Laan, B.F.A.M, van der Wal, J.E, Roodenburg, J.L.N

“…Summary Patients with pT1cN0 oral squamous cell carcinomas (OSCC) are generally not treated with a neck dissection (ND). However, in 25% of cN0 patients, nodal…”
Get full text